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ABSTRACT
Systemic lupus erythematosus (SLE) is the paradigm of 
systemic autoimmune diseases characterised by a wide 
spectrum of clinical manifestations with an unpredictable 
relapsing-remitting course. The aim of the present work 
was to identify current available clinical practice guidelines 
(CPGs) for SLE, to provide their review and to identify 
physicians’ and patients’ unmet needs. Twenty-three 
original guidelines published between 2004 and 2017 
were identified. Many aspects of disease management 
are covered, including global disease management, lupus 
nephritis and neuropsychiatric involvement, management 
of pregnancies, vaccinations and comorbidities monitoring. 
Unmet needs relate with disease management of some 
clinical manifestations and adherence to treatment. Many 
patient’s unmet needs have been identified starting with 
faster diagnosis, need for more therapeutic options, 
guidelines on lifestyle issues, attention to quality of life and 
adequate education.
INTRODUCTION
Systemic lupus erythematosus (SLE) is the 
paradigm of systemic autoimmune diseases 
characterised by a wide spectrum of clin-
ical manifestations with an unpredictable 
 relapsing-remitting course. While paediatric 
cases are described, SLE typically affects 
women between 16 years and 55 years. It is a 
heterogeneous condition, which may involve 
almost all organs and tissues. Some of the 
most common clinical features are mucocu-
taneous lesions, arthritis, renal involvement, 
haematological disorders, serositis and fever. 
Forty per cent to 70% of SLE patients suffer 
from lupus nephritis (LN) whose dominant 
feature is proteinuria usually associated with 
urinary sediment abnormalities. Between 
10% and 20% of patients with LN will develop 
chronic renal failure. Neuropsychiatric 
manifestations can also occur such as severe 
headache, seizure disorder, psychosis, acute 
confusional state and cognitive dysfunction. 
A higher rate of mortality and morbidity is 
associated with renal and neuropsychiatric 
involvements. The serological picture of 
SLE is characterised by the positivity of many 
autoantibodies among which the most specific 
are anti-dsDNA and anti-Sm. The presence 
of antiphospholipid antibodies is associated 
with a worse prognosis. During the course of 
SLE, patients may accrue both disease-related 
Key messages
What is already known about this subject?
 ► Systemic lupus erythematosus (SLE) is the paradigm 
of systemic autoimmune diseases characterised by 
a wide spectrum of clinical manifestations with an 
unpredictable relapsing-remitting course.
 ► A good number of Clinical Practice Guidelines are 
currently available on SLE.
What does this study add?
 ► This review represents a state of the art on existing 
Clinical Practice Guidelines and unmet needs in SLE.
How might this impact on clinical practice?
 ► In the framework of the European Reference 
Network on Rare and Complex Connective Tissue 
and Musculoskeletal Diseases (ERN ReCONNET), 
clinicians and patients will collaborate closely to 
address the unmet needs identified with the aim of 
harmonising the careprovided to SLE patients.
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and treatment-related damage. Although better use of 
available therapies has greatly improved outcome, SLE 
is still associated with a significant morbidity. In view 
of the large amount of specialists potentially involved 
in the daily care of SLE patients, as well as the various 
therapeutic approaches, it is important to establish a 
commonly shared treatment strategy. Clinical practice 
guidelines (CPGs) are systematically developed state-
ments to assist practitioner and patient decisions about 
appropriate healthcare for specific clinical circum-
stances.1 CPGs have been proposed for SLE, but they are 
sparse and not homogeneous. This manuscript intended 
is aimed at identifying current available CPGs for SLE 
and physician’s and patients’ unmet needs.
METHODS
ERN Rare CONnective tissue and musculoskeletal diseases 
NETwork (ReCONNET) SLE core set network
ERN ReCONNET is a European Reference Network 
funded by the European Union’s Health Program to 
promote better and safer healthcare, deﬁne proper 
organisational assessment and identify standard and 
cost-effective pathways for the management of Rare 
and Complex Connective Tissue Diseases. The network 
includes rheumatologists (adult and paediatric), intern-
ists and immunologists from 26 selected centres in eight 
different countries across Europe.
Within the ERN ReCONNET, the SLE core set network 
is composed of the members of the network involved in 
SLE, of FT and NC-C (the official SLE Disease Coordina-
tors, junior and senior) and of two methodologists of the 
ERN ReCONNET.
The SLE core set network is addressed to focus on the 
management of all forms of SLE disease manifestations, 
including rare and complex conditions.
One of the first core set network targets was to iden-
tify the currently available CPGs pertaining to SLE, in 
order to identify potential unmet needs, which should be 
further focused on. A literature search included all the 
papers published until July 2017. Analysis was conducted 
between June 2017 and February 2018. Planning and 
evaluation of the work was driven by regular interactions 
between participants of the working group during meet-
ings (European League Against Rheumatism - EULAR 
congress 2017, American College of Rheumatology -ACR 
congress 2017, ERN ReCONNET meeting in Pisa, 4-6 of 
February 2018), web conferences, emails and the ERN 
Collaborative Platform (https:// webgate. ec. europa. eu).
Systematic literature search
We carried out a systematic search in PubMed and 
Embase based on controlled terms (MeSH and Emtree) 
and keywords and on publication type (CPGs), in order 
to identify existing CPGs on diagnosis, monitoring and 
treatment, according to the Institute of Medicine 2011 
definition: clinical practice guidelines are statements that 
include recommendations intended to optimise patient care that 
are informed by a systematic review of evidence and an assess-
ment of the benefits and harms of alternative care options.
The search strategy is: MEDLINE (PubMed): (‘lupus 
erythematosus, systemic’[MeSH Terms] OR (‘lupus’[All 
Fields] AND ‘erythematosus’[All Fields] AND ‘system-
ic’[All Fields]) OR ‘systemic lupus erythematosus’[All 
Fields] OR (‘systemic’[All Fields] AND ‘lupus’[All 
Fields] AND ‘erythematosus’[All Fields])) AND (‘Prac-
tice Guideline’[Publication Type] OR ‘Practice Guide-
lines As Topic’[MeSH Terms] OR Practice Guideline 
[Publication Type] OR ‘Practice Guideline’[Text Word] 
OR ‘Practice Guidelines’[Text Word] OR ‘Guide-
line’[Publication Type] OR ‘Guidelines As Topic’[MeSH 
Terms] OR Guideline[Publication Type] OR ‘Guide-
line’[Text Word] OR ‘Guidelines’[Text Word] OR 
‘Consensus Development Conference’[Publication 
Type] OR ‘Consensus Development Conferences As 
Topic’[MeSH Terms] OR ‘Consensus’[MeSH Terms] OR 
‘Consensus’[Text Word] OR ‘Recommendation’[Text 
Word] OR ‘Recommendations’[Text Word] OR ‘Best 
Practice’[Text Word] OR ‘Best Practices’[Text Word]). 
Embase: (‘lupus erythematosus’/exp OR ‘chronic lupus 
erythematosus’ OR ‘lupus erythematodes’ OR ‘lupus 
erythematosus’ OR ‘lupus erythematosus’ OR ‘lupus 
erythematosus treatment’ OR ‘lupus syndrome’) AND 
('practice guideline'/exp OR ‘practice guideline’ OR 
‘practice guidelines’/exp OR ‘practice guidelines’ OR 
'clinical practice guideline'/exp OR ‘clinical practice 
guideline’ OR ‘clinical practice guidelines’/exp OR ‘clin-
ical practice guidelines’ OR 'clinical practice guidelines 
as topic'/exp OR ‘clinical practice guidelines as topic’ 
OR ‘guideline'/exp OR ‘guideline’ OR ‘guidelines’/exp 
OR ‘guidelines’ OR 'guidelines as topic'/exp OR ‘guide-
lines as topic’ OR ‘consensus development’/exp OR 
‘consensus development’ OR ‘consensus development 
conference’/exp OR ‘consensus development confer-
ence’ OR ‘consensus development conferences’/exp OR 
‘consensus development conferences’ OR ‘consensus 
development conferences as topic’/exp OR ‘consensus 
development conferences as topic’ OR ‘consensus’/exp 
OR ‘consensus’ OR ‘recommendation’ OR ‘recommen-
dations’) AND [embase]/lim NOT [medline]/lim.
In order to implement the list of guidelines provided by 
MEDLINE and Embase search, the group also performed 
a hand search.
Methodology of CPGs identification
All references included in the final list (systematic 
search+hand search) identified during the systematic 
literature search were screened for eligibility by two eval-
uators, the Disease Coordinators (NC-C and FT) of the 
ERN ReCONNET for SLE, based on title and abstract 
assessment. We addressed the following question: does 
this paper describe CPG? Manuscripts scored as such by 
at least one of the two evaluators were included in the 
next step.
The two evaluators then assessed all selected references 
with the full article in order to confirm that they were 
RMD Open
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CPGs. In case of no agreement, a further round of discus-
sion involving a third evaluator (LA) was performed, in 
order to reach consensus.
A discussion group was set up to confirm inclusion 
and evaluation of the selected CPGs. The topics covered 
by each guideline were systematically evaluated by one 
member of the group (FF) in order to guide the discus-
sion group during the identification of the unmet needs. 
Physician’s unmet needs were then defined by the group, 
each participant giving his thoughts regarding what is 
not currently addressed by the current guidelines.
Finally, the patient’s unmet needs paragraph intends 
to highlight the unmet needs of the European lupus 
community. The content of this paragraph has been real-
ised by the ERN ReCONNET European Patient Advo-
cacy Group that carefully collected the voices and the 
points of view of the whole European community of the 
disease they represent by means of meetings and web 
conferences.
RESULTS
State of the art on CPGs
Identification of existing CpGs
The systematic literature search yielded a total of 2272 
citations. Title and abstract evaluation identified 52 
papers suitable for full-text review. After full-text review, 
21 original guidelines were identified2–23 (figure 1. Of 
note, Saavedra et al published one guideline, which is 
divided into two parts with two different references, 
but this guideline was counted as one in the systematic 
search.15 16 Two articles were included by hand search,24 25 
leading to a total of 23 CPGs.
The general characteristics of the 23 CPGs are 
summarised in table 1. Twenty-one were in English 
(including one in both English and Portuguese8) and 
two in French. Sixteen guidelines had been endorsed/
supported by an official society or organisation: European 
League Against Rheumatism (EULAR) (n=8), American 
College of Rheumatology (ACR) (n=3), Brazilian Society 
of Rheumatology (n=1), European Union (SHARE initia-
tive) (n=2), Mexican College of Rheumatology (n=1) and 
Italian Society of Laboratory Medicine (n=1). The guide-
lines were published between 2004 and 2017 with only 
four published before 2010.
Five CPGs involved patient representatives and one 
involved a patient panel. Fifteen CPGs were dedicated to 
SLE, while eight covered a broader spectrum of rheumatic 
diseases (including SLE). Seventeen targeted all patients 
(juvenile and adult), four papers specifically targeted 
juvenile SLE and two female SLE. Five CPGs addressed 
general management of SLE, five addressed prevention 
or treatment of infections (three specifically focusing on 
vaccination), four focused on a specific SLE organ involve-
ment (three on renal disease and one on neuropsychiatric 
disease) two addressed immunologic laboratory testing, 
while others focused on pregnancy and family planning 
(n=2), cardiovascular risk management (n=2), cancer 
(n=1), orthopaedic perioperative management (n=1) or 
fatigue (n=1).
UNMET NEEDS
Clinicians’ unmet needs
This review provides an overview of currently available 
CPGs for SLE. Yet, there are several areas that are not 
(yet) covered by guidelines.
The following items were considered as correctly covered: 
(1) global management of SLE,5 10 14 20 22 including a treat-
to-target strategy22; (2) autoantibodies testing4 19; (3) 
Lupus
Figure 1 Flowchart constructed from Pubmed, Embase, and national databases.
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management of fatigue23; (4) monitoring for malignancies18; 
Screening and management of cardiovascular risk factors3 
and coronary disease risk monitoring21; (5) management 
(including treatment) of the two most severe manifesta-
tions of SLE, namely lupus nephritis7 11 (including in chil-
dren24) and neuropsychiatric involvement6; (6) prevention 
of infections13 with a focus on intestinal parasitic infections8; 
(7) vaccination in adults,25 in paediatric patients12 17 and in 
adolescents17; (8) pregnancy planning2 15 16 and manage-
ment of menopause2; and (9) Perioperative management 
for hip and knee surgery.9
By contrast, several clinician’s unmet needs were identi-
fied: (1) optimal management of serositis, gastrointestinal 
involvement, interstitial lung disease, retinal vasculitis, 
limited cutaneous disease, headaches and/or severe lymph-
opaenia that are not covered by the current available CPGs. 
(2) Evaluation and management of non-adherence to treat-
ment is a crucial missing point which is only addressed by 
one available CPG.10 (3) Optimal duration of immuno-
suppression, which is only partly addressed in some guide-
lines. (4) Patient’s input on CPGs is missing. Only one CPG 
proposed patient assessment as a recommendation, which 
consisted in an evaluation of her/his quality of life by using 
a visual analogue scale.14 (5) Except one CPG on LN,11 none 
of the available CPGs addressed the important question of 
ethnicity and its possible impact on disease severity. (6) No 
definition of photosensitivity and vasculitis is provided in 
current CPGs. (7) No mention of non-health related prog-
nostic determinants, such as patients’ socioeconomic status.
Patients' unmet needs
The first unmet need identified by patients deals with delay 
and uncertainty in diagnosis until confirmation by a specialist. 
This adds to the psychological burden of the disease, which 
might be aggravated if treatment is delayed. The need for 
new treatment options, less reliant on steroids and associ-
ated with fewer side effects, is a high priority for patients. 
They advocate a more holistic disease management, going 
beyond specific symptoms or an ‘organ by organ’ manage-
ment, to include a global treatment plan, coordinated by 
one physician, in casu a lupus expert, who treat them as a 
‘full person’ and takes care, besides the clinical aspects, of 
the psychological issues. In our working group meetings, 
lupus patients defined treatment as "any product or activity 
aiming at improving quality of life", clearly pinpointing the 
importance of a holistic approach. Patients are looking for 
scientifically validated patient focused guidelines on life-
style issues. Research should be conducted jointly by HCPs 
and patient organisations to identify behaviours or actions 
that can help patients take day-to-day ownership of their 
treatment, understanding what to do, or not to do, based 
on hard data. Even if remission of SLE disease activity has 
been achieved, many patients still face pain and fatigue. 
Understanding the drivers would allow building treatment 
guidelines for those conditions, which is critical to avoid that 
people facing these symptoms are pushed prematurely out 
of the labour market. Finally, while a huge amount of infor-
mation is available to patients on the web, this information 
is of very low quality, often counterproductive and anxiety 
generating. There is a need for high-quality therapeutic 
patient education and for an efficacious way to fight fake 
news that spread over the internet, for example, by quality 
certified information, or diffusion of ERN-endorsed recom-
mendations via social media posts.
CONCLUSIONS
Here we proposed an overview of the current available CPGs 
on SLE. Many unmet needs have been identified. Soon after 
we performed the systematic research, two clinical guide-
lines have been published.26 27 Gordon et al published the 
British guideline on SLE,26 which proposed recommen-
dations for some of these unmet needs, such as patient 
reported outcomes (Short Form (SF)-36 and Lupus QoL 
indices) and for immunosuppression duration. Pons-Estel 
et al27 published another guideline with a focus on socioec-
onomic and ethnic—namely in Latin Americans—aspects. 
Yet, many areas remain uncovered, and efforts are still 
needed to improve and standardise our daily practice.
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